Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Levobunolol hydrochloride
Drug ID BADD_D01268
Description A nonselective beta-adrenoceptor antagonist used in the treatment of glaucoma.
Indications and Usage For lowering intraocular pressure (IOP) and may be used in patients with chronic open-angle glaucoma or ocular hypertension.
Marketing Status Prescription; Discontinued
ATC Code S01ED03
DrugBank ID DB01210
KEGG ID D01025
MeSH ID D002040
PubChem ID 5284409
TTD Drug ID D00IUG
NDC Product Code 53296-0030; 24208-505; 0023-4385; 17337-0525; 65085-0029; 16436-0030
Synonyms Levobunolol | Apo-Levobunolol | Apo Levobunolol | ApoLevobunolol | Betagan | Levobunolol Hydrochloride | Novo-Levobunolol | Novo Levobunolol | NovoLevobunolol | W-7000A | W 7000A | W7000A | ratio-Levobunolol | ratio Levobunolol | Ultracortenol | Vistagan | AKBeta | PMS-Levobunolol | PMS Levobunolol | PMSLevobunolol
Chemical Information
Molecular Formula C17H26ClNO3
CAS Registry Number 27912-14-7
SMILES CC(C)(C)NCC(COC1=CC=CC2=C1CCCC2=O)O.Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Myasthenia gravis10.04.05.001; 17.05.04.001; 15.05.08.001--
Nasal congestion22.04.04.001--
Nausea07.01.07.001--
Palpitations02.01.02.003--
Paraesthesia17.02.06.005--
Pruritus23.03.12.001--
Rash23.03.13.001--Not Available
Refraction disorder06.02.04.004--Not Available
Respiratory failure22.02.06.002; 14.01.04.003--
Stevens-Johnson syndrome23.03.01.007; 12.03.01.014; 10.01.03.020; 11.07.01.005--
Syncope24.06.02.012; 17.02.04.008; 02.01.02.008--
Urticaria23.04.02.001; 10.01.06.001--
Visual impairment06.02.06.008--Not Available
Ocular discomfort06.08.03.008--Not Available
Erectile dysfunction21.03.01.007; 19.08.04.001--
The 2th Page    First    Pre   2    Total 2 Pages